Kinase, in vitro: 

An enzyme-substrate reaction that occurs in non-living experimental conditions such as a test tube. For example, a purified enzyme is reacted with a substrate protein or mixture of proteins or peptides.

Akt1 S897-p
EphA2 Y575-p , Y588-p , Y594-p , Y628-p , Y694-p , Y735-p , Y772-p , Y921-p , Y960-p
p90RSK S897-p
PKCA S892-p
PKCB S892-p
PKCZ S892-p
RSK2 S897-p
 Putative in vivo kinases: 

An enzyme-substrate reaction that occurs within living cells; includes cultured cells, ex vivo samples, and intact organisms. In the case of kinases, the large number of protein kinases in intact cells makes exact identification of the responsible kinase challenging.

EphA2 Y588-p , Y594-p , Y735-p , Y772-p
p90RSK S897-p
PKCA S892-p
PKCB S892-p
PKCZ S892-p
RSK2 S897-p
Phosphatases, in vitro:
PTPRF Y930-p
Putative upstream phosphatases:
ACP1 Y575-p , Y588-p , Y594-p , Y772-p , Y960-p
Regulatory protein:
ANXA1 S897-p
AREG S897-p
BRAF S897-p
C1GALT1 Y588-p
CSFR Y575-p , Y588-p , T593-p , Y594-p , Y772-p
EFNA1 S897-p
EFNA4 Y772-p , S897-p
EGFR Y575-p , Y594-p , Y772-p , S897-p
FGFR1 Y772-p
G-alpha 11 S897-p
KSR S897-p
MAPKAPK2 S897-p
P38A S897-p
p90RSK S897-p
RNF5 Y772-p , S897-p
RSK2 S897-p
TACE S897-p
TAK1 S897-p
TBK1 S897-p
THY1 S897-p
Treatment:
ALW-II-41-27 Y588-p , S897-p
angiotensin_2 S897-p , S901-p
anisomycin S897-p
BI-D1870 S897-p
BI-D1879 S897-p
BIRB-0796 S897-p
Candidalysin S897-p
cisplatin S897-p
conditioned medium S897-p
crizotinib S897-p
dabrafenib S897-p
dasatinib Y772-p
EGF Y575-p , Y772-p , S892-p , S897-p , S899-p , S901-p
ephrin_A1 Y588-p , Y594-p , Y735-p , Y772-p , S897-p
ephrin_B1 Y588-p , Y594-p , Y772-p , S897-p
ephrin_B2 Y588-p , Y594-p , Y772-p
FGF2 T587-p , Y594-p , Y772-p , S897-p
gefitinib Y588-p , Y594-p , S897-p , Y960-p
Ginsenoside Rg5 S897-p
Go_6983 S892-p , S897-p
GSK2334470 S897-p
heregulin S897-p
HGF Y588-p , Y594-p , Y772-p , S897-p
hypoxia S897-p
IL-1b S897-p
ionizing_radiation S897-p
ischemia S897-p
LJH589 S897-p
LPA S897-p
lupeol S897-p
LY294002 S897-p
MEDI3622 S897-p
metastatic potential S897-p , S899-p , S901-p
MG132 Y772-p , S897-p
MG132_withdrawal Y772-p
MK-2206 S897-p
MK2 inhibitor III S897-p
MK2_inhibitor_III S897-p
nocodazole S570-p , Y575-p , S579-p , T647-p
NVP-BHG712 S897-p
osmotic_stress S897-p
PD0325901 S897-p
PD166866 S897-p
PDGF S897-p
peptide S897-p
phorbol_ester S892-p , S897-p
regorafenib S897-p
SB202190 S897-p , S899-p , S901-p
SB203580 S897-p
SCH772984 S897-p
schisandrin C S897-p
selumetinib S897-p , S901-p
serum S897-p
Skepinone-L S897-p
SKI-606 S897-p
Su11274 Y575-p , Y588-p , Y594-p , Y772-p , S892-p , S897-p , T898-p , S899-p , S901-p , Y921-p
SU5402 S897-p
t-BHQ S897-p
tamoxifen S897-p
taxol S897-p
thymidine S570-p , Y575-p , S579-p , T647-p
TMI-005 S897-p
TNF S897-p
Trametinib S897-p
U0126 S892-p , S897-p , S901-p
vemurafenib S897-p , S901-p
VX702 S897-p